Practical answers, grounded in evidence
Questions that matter before and during weight-loss treatment. Explore 34 straightforward guides using clinical research and official prescribing information—even when the best evidence is several years old.
34 guides found
People taking a GLP-1 medicine sometimes hear conflicting advice before surgery or an endoscopy. In 2024, specialists from anesthesia, gastroenterology, obesity care and surgical organizations published joint guidance to help clinicians assess the situation. Their approach is individualized rather than a universal stop rule.
Read the guide →Pregnancy planning and contraception are easy to overlook when comparing weight-loss medicines. Eli Lilly's FDA prescribing information for tirzepatide, marketed as Zepbound, includes specific warnings about pregnancy and oral hormonal contraceptives. These instructions are important because not all medicines have identical interaction rules.
Read the guide →When starting a weight-loss medicine, one easily missed question is whether it affects medication you already take. Wegovy and Zepbound can slow stomach emptying, potentially changing how certain oral medicines are absorbed. The actual concern depends on your complete medication list and the formulation involved.
Read the guide →Vomiting and diarrhea are familiar GLP-1 side effects, but their consequences can go beyond discomfort. FDA prescribing information warns that fluid loss may contribute to acute kidney injury, especially when a person becomes dehydrated.
Read the guide →Weight-loss medications are not exclusively studied in adults, but pediatric use requires different evidence, eligibility criteria and clinical oversight. The FDA has approved certain prescription treatments for adolescents under particular conditions. That does not make every adult weight-loss drug suitable for a teenager.
Read the guide →Many people begin medication only after already making major lifestyle changes. The SURMOUNT-3 trial addressed this specific situation: researchers studied tirzepatide after participants had completed a 12-week intensive lifestyle program and lost at least 5% of their starting weight.
Read the guide →Nausea and abdominal discomfort can be common during treatment, but some abdominal symptoms need more attention. FDA prescribing information warns about pancreatitis and acute gallbladder disease with semaglutide-containing medicines and describes how clinicians should respond.
Read the guide →Weight-loss medications are sometimes discussed as if their only outcome is a smaller number on the scale. But the FDA approved a specific cardiovascular-risk indication for Wegovy injection in March 2024, based on an outcomes trial that looked at heart attack, stroke and cardiovascular death.
Read the guide →Moving a weekly injection day can make treatment easier during work, holidays or travel. But the spacing between doses matters. The FDA labels for Wegovy injection and Zepbound give different minimum intervals for changing the scheduled day.
Read the guide →Do you really need to keep increasing your weight-loss medication dose? Researchers have tested different doses, while FDA prescribing instructions explain which doses are considered maintenance treatment. The answer is more nuanced than simply 'higher is better'.
Read the guide →People sometimes consider changing medicines because of side effects, inadequate response, cost or insurance. Wegovy contains semaglutide and Zepbound contains tirzepatide. They are different medicines, so switching is a prescribing decision—not a simple conversion of one milligram number into another.
Read the guide →Some weight-loss medicines now have indications extending beyond weight management. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. That does not mean everyone who snores needs this medicine.
Read the guide →If you see an offer for a cheaper version of semaglutide or tirzepatide, the crucial question is whether the actual product is FDA-approved, legitimately compounded for a patient's medical need, or an unapproved product advertised online. Those categories are not equivalent.
Read the guide →People often hear that GLP-1 medicines lower blood sugar and worry about hypoglycemia. The actual risk depends on factors such as diabetes status and whether the person also takes insulin or certain other diabetes medicines.
Read the guide →A common misconception is that weight-loss medication was tested without any other support. In fact, the STEP 1 investigators combined semaglutide or placebo with lifestyle intervention. The SURMOUNT-1 tirzepatide trial also included lifestyle measures. This matters when people interpret published treatment results.
Read the guide →Losing body weight does not mean losing only body fat. A 2025 body-composition analysis of the SURMOUNT-1 study used DXA scans to measure fat mass and lean mass in people receiving tirzepatide. The results help readers understand what a bathroom scale cannot show.
Read the guide →Questions about nausea, vomiting and stomach symptoms are among the most practical concerns for people considering weight-loss medicines. FDA prescribing information explains both the more common reactions observed in studies and important warning signs that deserve medical assessment.
Read the guide →A common question is whether a weight-loss medicine can be stopped after reaching a target. Clinical trials have investigated what happens when treatment continues versus stops. This evidence helps explain why obesity is often managed as a longer-term condition.
Read the guide →Weight-loss advertisements often feature one impressive percentage. But what does that number really represent? In a large Eli Lilly-supported trial, researchers measured weight changes with different tirzepatide doses over 72 weeks. We explain how to use those averages without treating them as a promise.
Read the guide →Travel, delayed baggage and refrigeration worries are common for people using weekly injections. The most important detail is the exact medicine and device: single-dose pens, vials and multi-dose devices can have different time limits out of the refrigerator.
Read the guide →An ambitious goal like losing 50 pounds can make a smaller loss seem unimportant. But medical research and public health guidance recognize that losing a more modest share of starting weight may improve some health markers. This guide explains what percentages mean—and what they don't promise.
Read the guide →Missing a dose can happen during travel, illness or a pharmacy delay. The official product labels have specific instructions, and they are not identical for every injection or tablet. Using another drug's schedule could create avoidable problems.
Read the guide →For people with obesity and significant related health problems, the choice is not always between two medicines. Metabolic and bariatric surgery may also be an option. Medicines and surgery differ in eligibility, expected course, medical risks and follow-up requirements.
Read the guide →A pill may sound easier than an injection, but taking a weight-loss medicine by mouth doesn't automatically make it more convenient or effective. Available products have different ingredients, approved indications, schedules and instructions. Here's how to compare the practical differences.
Read the guide →Boxed warnings can sound frightening without context. The FDA's Zepbound prescribing information warns about thyroid C-cell tumors observed in rats exposed to tirzepatide and explains who should not use the medicine. This article separates what animal studies showed from what is known about risk in humans.
Read the guide →A 2022 follow-up study tracked weight changes after participants stopped semaglutide 2.4 mg.
Read the guide →A randomized study tested what happens after participants taking tirzepatide continue or stop treatment.
Read the guide →Not everyone loses the amount of weight shown in an advertisement or trial average. Some people respond less, others struggle with tolerability, and a few cannot reach a maintenance dose. An inadequate response is a reason to review your care—not a reason to double doses.
Read the guide →Many people experience a period when the scale stops moving even though they continue their prescription. Before calling the medication ineffective, it helps to distinguish a normal slowing of weight loss from issues such as missed doses, a change in health, or a treatment response that needs clinical review.
Read the guide →It's common to see rapid early changes on a weight-loss medicine and then slower progress. A research team from academic medical centers and Eli Lilly examined when participants taking tirzepatide reached a plateau, rather than assuming that one difficult month meant treatment had stopped working.
Read the guide →A weekly injection is straightforward only once you know the correct medicine, pen or vial and technique. Patients often ask whether they should inject into the abdomen, thigh or arm—and whether using the same area repeatedly is acceptable.
Read the guide →When people ask whether they qualify for weight-loss medication, the answer isn't based on weight alone. Researchers in the STEP 1 study enrolled adults using a combination of body mass index (BMI) and health conditions. Actual prescribing decisions also depend on each medicine's current FDA-approved indications and individual safety considerations.
Read the guide →Older employer-benefit research explains why insurance coverage can differ even between people taking the same medicine.
Read the guide →Understand why better long-term vitality and fatigue during treatment are not contradictory—and what clinical trials can actually tell us.
Read the guide →Educational information, not personal medical advice. Always check the latest label for your specific medicine and consult your care team.